Month: February 2022

AOBiome Therapeutics’ topical biotherapeutic B244 demonstrated positive Phase 2b results from its 547 patient trial for both Pruritus (Itch) and Appearance in its 547 patient Phase 2b trial of Atopic Dermatitis (Eczema)

CAMBRIDGE, Mass., Feb. 22, 2022 /PRNewswire/ -- AOBiome Therapeutics, a clinical stage biotechnology company focused on transforming human health by developing...

Global Demand on Digital Patient Monitoring Devices Market Flourishing – Projected to Reach Worth USD 447.3 Billion by 2028: Zion Market Research

NEW YORK, Feb. 22, 2022 /PRNewswire/ -- As per the findings of Zion Market Research study, Digital Patient Monitoring Devices industry accumulated...

error: Content is protected !!